FOR IMMEDIATE RELEASE
Stacy Rubenstein, (847) 949-2286
Managing Supply Chain Costs: Medline Strikes New Group Purchasing Agreement with Blood Centers of America
55 member centers to benefit from negotiated pricing and cost savings on medical-surgical supplies
Mundelein, Ill., Dec. 30, 2015 – In a constant evolving industry, healthcare organizations look to manufacturers and distributors to assist them with efficiency. To help manage supply chain costs amongst its members, Blood Centers of America (BCA), the nation’s largest blood supply network that represents nearly 40 percent of the U.S. blood supply, has inked a group purchasing agreement with Medline, a global manufacturer of medical supplies and clinical solutions.
The three-year deal is expected to provide BCA’s 50-plus member centers nationwide with negotiated pricing and cost savings on a wide range of medical-surgical supplies. Products covered in the agreement include personal protective apparel, exam gloves and medical consumable products.
“Medline is committed to providing high quality supplies to ensure BCA’s member facilities are able to perform at their very best when providing such services as cell therapies, cord blood banking and blood management,” said Joe Waldron, vice president of national accounts, Medline. “As a leading manufacturer of medical-surgical supplies, we are dedicated toward utilizing our supply chain expertise to help enhance BCA’s supply chain efficiencies.”
Furthermore, Medline understands the importance of customers receiving products in a timely manner. With 40 distribution centers strategically located throughout the country, BCA’s member centers are able to receive their crucial supplies where and when they need them.
“BCA is very excited with our new distribution agreement with Medline, as it will complement our existing phlebotomy and donor screening kitting agreement launched earlier this year. Medline’s unique distribution capabilities in conjunction to their manufacturing portfolio offer a vast array of solutions which will enable our centers to achieve their clinical, operational and financial goals,” said Sam Keith, vice president, supply chain and national accounts, Blood Centers of America. “We fully expect our partnership will continue to evolve into much more than the traditional relationship of just shipping supplies to our centers. We are enthusiastic on the long term prospects of what these opportunities will offer our collective organizations in the future.”
The contract is effective through July 31, 2018.
Medline is a global manufacturer and distributor serving the healthcare industry with medical supplies and clinical solutions that help customers achieve both clinical and financial success. Headquartered in Mundelein, Ill., the company offers 350,000+ medical devices and support services through more than 1,200 direct sales representatives who are dedicated points of contact for customers across the continuum of care. For more information on Medline, go to www.medline.com or http://www.medline.com/social-media to connect with Medline on its social media channels.
BCA is a member-owned organization comprised of more than 50 independent blood centers geographically dispersed throughout the North America, representing nearly 40 percent of the U.S. blood supply. Along with their core business of providing a substantial portion of U.S. blood supply, BCA members provide a variety of other services including, patient blood management, transfusion services, immunohematology testing, therapeutic apheresis and tissue and cord blood banking. In addition, BCA members provide a variety of human blood products, cells and tissues to the therapeutic, diagnostic and cell therapy industries. Learn more at http://www.bca.coop/.
In a first-of-its-kind pilot, the San Diego Blood Bank (SDBB) is launching a program to enable community volunteers to participate in genomics research. The objective of the pilot program is to develop a model for population-scale research that is truly participant-centric and cultivates long-term participant engagement for maximum diversity and research potential with the ultimate goal of improving human health. The goal of the pilot program is also ultimately aligned with the goal of enabling volunteers to participate in the Precision Medicine Initiative (PMI), which was announced by President Obama in his 2015 State of the Union Address. The PMI is intended “to bring us closer to curing diseases like cancer and diabetes – and to give all of us access to the personalized information we need to keep ourselves and our families healthier.”
Charlie Miraglia, M.D. Announced as New CEO of Indiana Blood Center
Prominent healthcare executive set to become new leader for non-profit’s new era
Indianapolis, Ind. (October 12, 2015) – Charles C. Miraglia, M.D., a prominent healthcare executive, has been named the new president and CEO of Indiana Blood Center, a part of Versiti, the state’s largest independent blood provider and preeminent experts on transfusion medicine serving hospitals throughout Indiana and the Midwest.
FOR IMMEDIATE RELEASE: CONTACT: Joseph Yelo, MBA, MT (ASCP) SBB
Thursday, August 20, 2015 Lead Executive, Business & Community Development 302-737-8405 ext. 866 email@example.com
BBD Produces INTERCEPT Pathogen Reduced Platelet Units
Newark, DE – The Blood Bank of Delmarva (BBD) announced today the production of pathogen reduced platelets. BBD was the first blood center to sign an agreement with Cerus Corporation following the FDA approval received for the INTERCEPT Blood System for platelets and plasma in December 2014. BBD provides blood transfusion products and services to hospitals and patients in the Delmarva region which includes the State of Delaware, Maryland, as well as portions of the Eastern Shores of Maryland and Virginia. BBD supplies approximately 13,000 platelet and 21,000 plasma units per year.
The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as Chikungunya, Malaria and Dengue. “I am pleased that BBD is able to offer pathogen reduced platelets to our hospitals and their patients. This product provides a greater level of safety by lowering the risk for transfusion-transmitted infections,” says Chris Nare, Lead Executive of Laboratory Services and Distribution at BBD.
The implementation of the INTERCEPT Blood System aligns with BBD’s mission of providing safe and effective blood products that best serve the local hospital and patient community. “The INTERCEPT product closely aligns with our vision of being a Best in Class Blood Bank and Community Partner. Offering pathogen reduced platelets to the hospitals we serve is a major milestone of our ongoing focus on innovation that supports patient wellbeing,” states Roy Roper, President and Chief Executive Officer of BBD.
About Blood Bank of Delmarva
The Blood Bank of Delmarva (BBD) is a not-for-profit 501(c) (3) community service organization which provides blood transfusion products and services for hospitals within the Delmarva region which includes Delaware as well as Maryland. BBD supplies approximately 75,000 red cell, 13,000 platelet, and 21,000 plasma units per year. For over 60 years, Blood Bank of Delmarva has ensured a safe and continuous supply of blood to meet the needs of over 20,000 patients annually. In addition to blood provisioning, BBD operates a full service regional laboratory providing donor testing and patient reference laboratory services for other blood collection centers and hospitals. BBD is FDA licensed, a member of America’s Blood Centers, and accredited by AABB.
For more information about the Blood Bank or to schedule an appointment, visit www.DelmarvaBlood.org or call 1-888-8-BLOOD-8.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
Sacramento, CA – BloodSource today announced that its Board of Directors has appointed Rob Van Tuyle as Chief Executive Officer (CEO), succeeding former CEO Mike Fuller who recently retired.
“Rob is a highly respected leader in the national and global blood banking community through his involvement with various industry associations and international plasma programs,” said Michael Lucien, MD and Chair of the BloodSource Board of Directors. “As the healthcare industry evolves at a rapid pace, we are confident that Rob’s vision will help BloodSource continue to grow and increase its positive impact on the lives of many patients.”
Rob joined BloodSource as Chief Financial Officer in 2010, and was named President of BloodSource in 2014. Van Tuyle has extensive experience in financial management, strategic planning and operations. In 2012, Sacramento Business Journal named him ‘CFO of the Year.’ Additionally, Rob serves on the Board of the Sacramento Metro Chamber of Commerce.
“BloodSource makes a tremendous difference for many patients and their families within our communities and around the world,” said Van Tuyle. “It all starts with the generosity of our donors who truly give of themselves to help save lives. I am very honored to lead this remarkable organization.”
Prior to BloodSource, Rob served as an auditor for Ernst & Young in Palo Alto, CA for 10 years, and later as CFO for a number of venture-backed, technology companies located in the Sacramento area including SynapSense Corporation, Sierra Logic and ShareWave. Rob represents BloodSource as a member of the board and executive committee member of Blood Centers of America (BCA) and is chairman of the plasma committee with BCA. Rob received his Bachelor of Science degree in Business from the University of Santa Clara and is a certified public accountant in the state of California.
Established in 1948 as a not-for-profit community blood bank, BloodSource serves a population of over 5 million and provides blood and medical expertise to over 40 hospitals in the Northern and Central California regions. With 15 BloodSource Donor Centers and over 2,200 mobile drives annually, BloodSource relies on volunteer donors, chairpeople and volunteers to ensure that community blood needs are always met. Together, we do save lives.
Approach provides comprehensive genetic diagnosis for patients with rare genetic bleeding disorders
MILWAUKEE, July 13, 2015 /PRNewswire-USNewswire/ — BloodCenter of Wisconsin’s Diagnostic Laboratories, part of Versiti™, today announced the availability of genetic deletion/duplication analysis. Using array Comparative Genomic Hybridization (aCGH), this test provides timely detection of deletions and/or duplications which may escape detection with standard DNA sequencing tests. BloodCenter pairs deep clinical hematology expertise with leading edge technology in genomic medicine to provide physicians comprehensive analyses for patients with rare bleeding disorders such as hemophilia or von Willebrand disease.
BloodCenter’s test allows for the detection of deletions and duplications within a given gene, whether within a single exon, encompassing one or more exons, or the entire gene.
“BloodCenter of Wisconsin is well known for its expertise in non-malignant blood disorders,” says Rupa Udani, director of BloodCenter’s molecular diagnostics laboratory. “We now are able to determine the underlying genetic cause of hematologic disease for patients, which was previously not possible using DNA sequencing alone.”
Clinical consultation with follow-up testing recommendations for patients and at-risk family members
Genetic consultation to physicians to ensure appropriate testing algorithm
Because BloodCenter has the ability to interpret aCGH test results with sequencing results, we can provide physicians with a comprehensive genetic analysis to enhance patient care. Visit our website to view the test description.
BloodCenter’s Diagnostic Laboratories help physicians provide clinical care to patients worldwide, fostering better understanding and treatment options for patients with difficult-to-diagnose diseases. In addition, the laboratories collaborate with other institutions and industry partners to bring new diagnostic testing and treatment options to patient care.
About BloodCenter of Wisconsin BloodCenter of Wisconsin, part of Versiti, is a not-for-profit organization that specializes in blood services, diagnostic testing, organ, tissue and marrow donation, medical services and leading-edge research. BloodCenter of Wisconsin is the only provider of blood to hospitals in 29 Wisconsin counties as well as providing support to hospitals and patients across the country. BloodCenter of Wisconsin advances patient care by delivering life-saving solutions grounded in unparalleled medical and scientific expertise. For more information, visit www.bcw.edu.
About Versiti Versiti was formed with the mission to improve the health of patients and enable the success of its healthcare partners nationally. We provide innovative, value added solutions in the fields of transfusion medicine, transplantation, and blood-related diseases to meet the needs of each of our customers. The collective efforts of Versiti affiliates result in improved patient outcomes, expanded access to care and cost efficiencies for healthcare systems nationwide. For more information, visit www.versiti.org.
GRAND RAPIDS, Mich. (June 15, 2015) – Jim Wilson has been appointed Chief Operating Officer (COO) for Michigan Blood. As COO, Wilson will be responsible for leadership of all aspects of operations including blood collection, donor safety and specialty testing, component preparation, product inventory management, order fulfillment and distribution, facilities management, and equipment and vehicle support services.
Wilson comes to Michigan Blood with extensive experience in a variety of senior healthcare leadership roles, most recently as Chief Operating Officer at Mary Free Bed Rehabilitation Institute in Grand Rapids. Prior to Mary Free Bed, Wilson was President of Blodgett Hospital and Vice President of Operations at Spectrum Health. Wilson also held a variety of senior leadership roles, including CEO, at hospitals in Long Island, NY.
Wilson earned his M.A. in Health Care Administration, The George Washington University, Washington, D.C., and a B.A. in Economics from The University of Notre Dame, South Bend, Indiana. He is a Fellow of the American College of Healthcare Executives.
Wilson has been an active civic and community member. He currently is a member and Former Chair of the Catholic Central High School Development Council, a member of the Dominican Sisters of Grand Rapids Investment Advisory Committee / Charitable Trustees, and a member of the Finance Council for St. Robert of New Minster Parish in Ada.
About Michigan Blood:
Founded in 1955, Michigan Blood is an independent, nonprofit, blood bank that provides blood for hospitals across Michigan’s Lower Peninsula. Michigan Blood is committed to serving the needs of Michigan hospitals first. Besides blood donation at permanent donation sites, Michigan Blood conducts more than 3,700 mobile blood drives each year. Other related services include Michigan’s first public cord blood bank, blood stem cell (marrow) program, transfusion medicine consultation, transplant center support, and other services. For more information, visit www.miblood.org.
April 23, 2015 – Milwaukee, Wis. — The Centers for Transfusion and Transplant Medicine (CTTM), an affiliation of four Midwest blood centers, has unveiled a new name, logo and expanded areas of expertise to better reflect the value it provides to its healthcare partners. CTTM will now be known as Versiti.
“In an era of unprecedented change in healthcare, there is significant opportunity for blood centers to work closely with our healthcare system partners to support them in reaching their goals of improved patient outcomes, expanded access to care, and cost efficiencies,” said Peter Ziegler, Versiti board chair. “Having brought four blood centers together, we are well on our way to delivering enhanced value to our partners and communities.”
The four Versiti™ affiliates are BloodCenter of Wisconsin, Heartland Blood Centers, Aurora, Ill., Indiana Blood Center and Michigan Blood.
“Versiti provides even greater value to healthcare systems in our communities and across the country through our five areas of expertise,” said Jacquelyn Fredrick, president and CEO of Versiti. “Our new name and logo better reflect the depth and breadth of this expertise and the diversity of our innovative science, products and services,” said Fredrick.
Versiti serves its healthcare partners through five areas of expertise:
“Through our vast knowledge of the science and medicine of blood, we not only provide life-saving transfusions, transplants and treatment for patients with blood diseases,” said Fredrick. “Versiti also contributes to breakthroughs in molecular immunology, cellular therapies and through pioneering gene therapies.”
The Versiti name itself was built with a specific meaning. “Ver” communicates truth, accuracy and versatility; while “siti” suggests university and diversity – diverse and innovative science, products and services impacting a broad array of patients.
The logo is a focal point of bands and illumination of color which come together signifying strength and the broad array of services being offered through Versiti.
About Versiti Versiti was formed with the mission to improve the health of patients and enable the success of our healthcare partners nationally. We provide innovative, value added solutions in the fields of transfusion medicine, transplantation, and blood-related diseases to meet the needs of each of our customers. The collective efforts of Versiti affiliates result in improved patient outcomes, expanded access to care and cost efficiencies for healthcare systems nationwide. For more information, visit
San Antonio Business Journal honors BioBridge Global CEO Linda Myers with Health Care Heroes awardWork on World Stem Cell Summit, transforming subsidiaries into global companies noted
SAN ANTONIO – We’re proud to announce that BioBridge Global CEO Linda Myers has been named one of the winners of the 2015 Health Care Heroes awards, given each year by the San Antonio Business Journal.
Myers was one of the winners in the category of Outstanding Health Care Executive – Nonhospital-Based.
BioBridge Global (BBG) board members Mike Kreager and John Feik submitted letters in support of Myers’ nomination, as did Dr. Steve Davis and Ann Stevens. Davis is a co-founder of San Antonio-based biomedical firm StemBioSys Inc.; and Stevens is president of BioMed SA, a nonprofit organization that supports the biomedical industry in our city.
“I am honored to have received this award and the support of the board,” Myers said. “It is through the efforts of the entire organization and our employees working toward our mission to save and enhance lives that we are at the forefront of the medical and regenerative medicine industries. I’d like to thank everyone at BioBridge Global who works diligently every day to help us improve the lives of those who are ill and injured. BioBridge Global serves patients and supports research opportunities through the continued collaborations with our biomedical community partners.”
Specific accomplishments that supported Myers’ nomination were helping to bring the World Stem Cell Summit to San Antonio in December 2014, her work in transforming BBG subsidiary QualTex Laboratories into an international leader in infectious disease testing and her vision to build BBG subsidiary GenCure into a major regenerative medicine resource.
The SABJ will honor the recipients at a reception on May 28 at the Tobin Center for the Performing Arts.
About BioBridge Global: BioBridge Global (BBG) is a San Antonio, Texas-based nonprofit corporation that offers diverse services through its subsidiaries – the South Texas Blood & Tissue Center, QualTex Laboratories, GenCure and the Blood & Tissue Center Foundation. BBG provides products and services in blood resource management, cellular therapy, donated umbilical cord blood and human tissue as well as testing of blood, plasma and tissue products for clients in the United States and worldwide. BBG is rooted in the South Texas Blood & Tissue Center, which has a proud history of serving the South Texas region and beyond for more than 40 years. BBG is committed to supporting groundbreaking research, addressing unmet clinical needs and enabling the development and commercialization of novel biotechnology products. Visit us at www.biobridgeglobal.org.